SHPH

#5059
Shuttle Pharmaceuticals Holdings, Inc. - common stock
3.8 0 USD
+0.23%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
3.56
4.10
Year Range
0.38
6.15
Daily Change
+22.98%
Monthly Change
+20.25%
6 month change
+251.85%
Year Change
+251.85%
Previous Close
3.0 9
Open
3.7 3
Low
3.5 6
High
4.1 0
Volume
679
Open full chart

Financials

Overview Statement Statistics Documents

2026

Current report, Q2 FY2026
Shuttle Pharmaceuticals Holdings, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Shuttle Pharmaceuticals Holdings, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Shuttle Pharmaceuticals Holdings, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Shuttle Pharmaceuticals Holdings, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Shuttle Pharmaceuticals Holdings, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Shuttle Pharmaceuticals Holdings, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Shuttle Pharmaceuticals Holdings, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Shuttle Pharmaceuticals Holdings, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Shuttle Pharmaceuticals Holdings, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Shuttle Pharmaceuticals Holdings, Inc. current report, Q1 FY2026
8-K

Shuttle Pharmaceuticals Holdings, Inc. current report, Q2 FY2025

Business Context and Reporting Period

This Form 8-K filing by Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reports a significant corporate event dated May 21, 2025. The company, an emerging growth company incorporated in Delaware, operates in the pharmaceutical sector with principal offices in Gaithersburg, Maryland.

Key Financial Metrics

The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The report focuses exclusively on a material change to employee compensation structures rather than periodic financial performance data.

Material Changes

On May 21, 2025, the Company implemented a 70% salary reduction for all salaried employees and executive officers. This action affects the following key personnel:

  • Christopher Cooper (Interim Chief Executive Officer)
  • Peter Dritschilo (President and Chief Operating Officer)
  • Mira Jung (Chief Scientific Officer)
  • Tyvin Rich (Chief Clinical Officer)
  • Michael P. Vander Hoek (Vice President, Regulatory)

Additionally, Timothy Lorber (Chief Financial Officer) agreed to a variation of this reduction where 70% of his salary will be deferred and paid at a later date.

Outlook, Risks, and Management Commentary

The filing does not contain forward-looking guidance, specific risk factors, or management commentary regarding future operational plans beyond the immediate salary adjustments. The drastic reduction in executive and employee compensation suggests a severe liquidity constraint or a strategic pivot to extend the company's cash runway, though the filing text does not explicitly state the underlying financial distress or strategic rationale.

Investor Verification Checklist

  • Verify the Company's current cash position and runway in the most recent 10-Q or 10-K filing.
  • Confirm if the salary deferral for the CFO includes interest or specific repayment terms.
  • Assess the impact of the 70% pay cut on employee retention and operational continuity.
  • Review recent press releases or investor presentations for context on the financial necessity of these cuts.

News